Skip to content
Evigrade
CriticalPharmacokinetic enhancer (booster) for antiretroviral therapy×Antiepileptics. Barbiturates

Updated · Methodology

Mechanism

Phenobarbital is a potent inducer of drug-metabolising enzymes (cytochromes P450 and glucuronosyltransferases) and of the transporter P-glycoprotein (P-gp), so it can speed up the elimination of many drugs and weaken their effect (phenobarbital summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The cobicistat SmPC and label list phenobarbital among strong CYP3A inducers, and CYP3A metabolises both cobicistat and the atazanavir or darunavir it boosts (cobicistat SmPC, European Medicines Agency, EMA, and label, US Food and Drug Administration, FDA). The levels of cobicistat and of the boosted drug may fall, human immunodeficiency virus (HIV) treatment may lose its effect, and the virus may become resistant (cobicistat SmPC, EMA). For the darunavir/cobicistat/emtricitabine/tenofovir alafenamide tablet, the SmPC also expects phenobarbital to reduce the absorption of tenofovir alafenamide by inducing P-gp (SmPC of this product, EMA). The documents do not describe any effect of cobicistat on phenobarbital.

Symptoms

The fall in the levels of cobicistat and of the boosted drug causes no symptoms by itself. The main risk is that the antiviral regimen loses its effect and human immunodeficiency virus (HIV) becomes resistant to the drugs (cobicistat summary of product characteristics, SmPC, European Medicines Agency, EMA, and label, US Food and Drug Administration, FDA). Laboratory tests, not how the person feels, show a loss of virologic response (cobicistat FDA label).

Management

The combination is contraindicated. Phenobarbital is on the cobicistat contraindication list together with carbamazepine and phenytoin. As strong CYP3A inducers, they can lower the levels of cobicistat and of the drug it boosts, and treatment may lose its effect (cobicistat summary of product characteristics, SmPC, European Medicines Agency, EMA, and cobicistat label, US Food and Drug Administration, FDA). The same contraindication appears in the SmPCs of the combination tablets of cobicistat with darunavir, atazanavir and elvitegravir (SmPCs of these products, EMA). The phenobarbital SmPC does not name cobicistat, but it contraindicates atazanavir, one of the two drugs that cobicistat is taken with (phenobarbital SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, and cobicistat SmPC, EMA). For a person taking cobicistat, choose seizure treatment without phenobarbital, carbamazepine or phenytoin (cobicistat SmPC, EMA, and FDA label). No document gives an interval between stopping phenobarbital and starting cobicistat. Do not stop phenobarbital abruptly; reduce the dose gradually (phenobarbital SmPC, AEMPS). Before starting cobicistat and during treatment, consider possible interactions, review all concomitant medicines and monitor for their adverse effects (cobicistat FDA label).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Cobicistat

Other interactions with Phenobarbital